Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARL | Q9H300 | 2/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL476998 | 0.90 | PSIP1 (0.47) | PARLHTR6PSIP1TDP1ALDH1A1 | |
| SCHEMBL1954965 | 0.88 | PARL (0.41) | PARLHTR6PSIP1TDP1ALDH1A1 | |
| SCHEMBL3448669 | 0.88 | PARL (0.41) | PARLHTR6PSIP1TDP1ALDH1A1 | |
| SCHEMBL3446801 | 0.88 | PARL (0.41) | PARLHTR6PSIP1TDP1ALDH1A1 | |
| SCHEMBL3447252 | 0.85 | PSIP1 (0.45) | PARLHTR6PSIP1TDP1ALDH1A1 | |
| SCHEMBL11049643 | 0.85 | PARL (0.44) | PARLHTR6PSIP1TDP1ALDH1A1 | |
| SCHEMBL16047188 | 0.84 | PARL (0.38) | PARLPSIP1TDP1ALDH1A1MAPT | |
| SCHEMBL4342079 | 0.83 | PARL (0.43) | PARLHTR6PSIP1TDP1ALDH1A1 | |
| SCHEMBL4330200 | 0.83 | PARL (0.43) | PARLHTR6PSIP1TDP1ALDH1A1 | |
| SCHEMBL2057595 | 0.83 | PSIP1 (0.43) | PARLHTR6PSIP1TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399428-A1 | SYSTEMS, METHODS AND HYDROGELS FOR CELL CULTURE AND ANALYSIS | PHENOMEX INC. (US) | 2020-12-24 | — | — | US | claimed |
| EP-3681935-A2 | SYSTEMS, METHODS AND HYDROGELS FOR CELL CULTURE AND ANALYSIS | Evorion Biotechnologies GmbH (DE) | 2020-07-22 | — | — | EP | claimed |
| WO-2019048714-A2 | SYSTEMS, METHODS AND HYDROGELS FOR CELL CULTURE AND ANALYSIS | EVORION BIOTECHNOLOGIES GMBH (DE) | 2019-03-14 | — | — | WO | claimed |
| CN-120161690-A | Toner and method for producing the same | 佳能株式会社 | 2025-06-17 | — | — | CN | disclosed |
| US-20200399428-A1 | SYSTEMS, METHODS AND HYDROGELS FOR CELL CULTURE AND ANALYSIS | PHENOMEX INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200282397-A1 | SYSTEMS, METHODS AND HYDROGELS FOR CELL CULTURE AND ANALYSIS | PHENOMEX INC. (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3681935-A2 | SYSTEMS, METHODS AND HYDROGELS FOR CELL CULTURE AND ANALYSIS | Evorion Biotechnologies GmbH (DE) | 2020-07-22 | — | — | EP | disclosed |
| EP-3681636-A1 | SYSTEMS, METHODS AND HYDROGELS FOR CELL CULTURE AND ANALYSIS | Evorion Biotechnologies GmbH (DE) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019048714-A2 | SYSTEMS, METHODS AND HYDROGELS FOR CELL CULTURE AND ANALYSIS | EVORION BIOTECHNOLOGIES GMBH (DE) | 2019-03-14 | — | — | WO | disclosed |
| US-9065146-B2 | Nonaqueous electrolyte and lithium secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-06-23 | — | — | US | disclosed |
| US-8551662-B2 | Nonaqueous electrolyte and lithium secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20070238025-A1 | NONAQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-10-11 | — | — | US | disclosed |
| US-7223502-B2 | Nonaqueous electrolyte and lithium secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-05-29 | — | — | US | disclosed |
| US-20050124807-A1 | oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound | KOEI CHEMICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
| US-20050118512-A1 | Nonaqueous electrolyte and lithium secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-06-02 | — | — | US | disclosed |
| US-4170707-A | Method for preparing 3,8-dicarbomethoxy-2,3,7,8-tetraazaspiro[4.4]nona-1,6-diene | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1979-10-09 | — | — | US | disclosed |
| US-4170706-A | Method for preparing the bispicrate salt of 2,3,7,8-tetraazaspiro[4.4]nonane | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1979-10-09 | — | — | US | disclosed |
| US-4125728-A | Method for preparing 2,3,7,8-tetraazaspiro[4,4]nona-2,7-diene | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1978-11-14 | — | — | US | disclosed |
| US-4066833-A | 2,3,7,8-Tetraazaspiro [4.4]nonane, 2,3,7,8-tetraazaspiro-[4.4]nona-2,7-diene and derivatives | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1978-01-03 | — | — | US | disclosed |
| US-3994972-A | Synthesis of N,N',N\",N'\"-tetra-salicylidene pentaerythrityl tetramine | HORIZONS INCORPORATED, A DIVISION OF HORIZONS RESEARCH INCORPORATED (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124807-A1 | oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound | ADH1C, ADH1A, AOX1 | PARL 4210/4885HTR6 652/4885PSIP1 3955/4885 |
| US-20200399428-A1 | SYSTEMS, METHODS AND HYDROGELS FOR CELL CULTURE AND ANALYSIS | HLCS, CD63, CD44 | PARL 3126/4885HTR6 2144/4885PSIP1 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.